Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Ultragenyx: Q4 Earnings Snapshot

Ultragenyx: Q4 Earnings Snapshot

RARE : 46.60 (-0.47%)
Ultragenyx: Q3 Earnings Snapshot

Ultragenyx: Q3 Earnings Snapshot

RARE : 46.60 (-0.47%)
Ultragenyx: Q2 Earnings Snapshot

Ultragenyx: Q2 Earnings Snapshot

RARE : 46.60 (-0.47%)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 20.81 (+0.19%)
RARE : 46.60 (-0.47%)
SRPT : 128.54 (-1.30%)
PFE : 28.06 (+1.01%)
EXEL : 23.82 (-0.17%)
MRNA : 107.39 (-2.89%)
UTHR : 232.85 (-4.28%)
BIIB : 214.99 (-0.62%)
SNY : 48.78 (-1.53%)
LLY : 782.69 (+0.58%)
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

REGN : 960.37 (-0.61%)
RARE : 46.60 (-0.47%)
APTX : 0.0960 (+3.11%)
ETNB : 11.49 (+1.59%)
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -18.27% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RARE : 46.60 (-0.47%)
THMO : 0.7490 (+6.51%)
Ultragenyx: Q1 Earnings Snapshot

Ultragenyx: Q1 Earnings Snapshot

RARE : 46.60 (-0.47%)
Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of -7.94% and 35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ALLO : 4.45 (-0.22%)
RARE : 46.60 (-0.47%)
Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZYME : 10.50 (+1.94%)
RARE : 46.60 (-0.47%)
Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

RARE : 46.60 (-0.47%)
GMAB : 29.95 (-2.22%)

Barchart Exclusives

This Bausch Health Companies Unusually Active Option Is a No-Brainer
Bausch Health Companies had the 8th-highest Vol/OI ratio in Wednesday trading. The pharmaceutical company’s unusual options activity suggests it might have more gains ahead. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar